Evidence map›Paper›PMID 30617763›Full record

ArticleAdvances in therapy2019

Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.

Hayley M de Freitas, Tetsuro Ito, Monica Hadi, Gemma Al-Jassar, Mickaël Henry-Szatkowski, Beenish Nafees, Andrew J Lloyd

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Hayley M de FreitasPatient Centered Outcomes, Mapi, An Icon plc Company, London, UK.
Tetsuro ItoHealth Economics and Market Access EMEA, Janssen, High Wycombe, UK. tito6@its.jnj.com.
Monica HadiPatient Centered Outcomes, Mapi, An Icon plc Company, London, UK.
Gemma Al-JassarPatient Centered Outcomes, Mapi, An Icon plc Company, London, UK.
Mickaël Henry-SzatkowskiPatient Centered Outcomes, Mapi, An Icon plc Company, Lyon, France.
Beenish NafeesNafees Consulting Ltd, London, UK.
Andrew J LloydAcaster Lloyd Consulting Ltd, London, UK.
Janssen (United Kingdom) · GBLloyd's · GBMapi Research Trust · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVarious treatment options are available for metastatic hormone-sensitive prostate cancer. This study aimed to quantify how men with prostate cancer in the United Kingdom (UK), Germany, and Spain perceive the risks and benefits of hypothetical abiraterone acetate plus prednisone treatment and docetaxel-based chemotherapy treatment options.

methodsA targeted literature review, exploratory interviews with prostate cancer patients and oncologists, and pre-test interviews were used to develop a discrete choice experiments (DCE). The final DCE included 32 choice sets, selected using a main-effects orthogonal design, divided into two survey blocks. Paired profiles presented hypothetical treatments for prostate cancer through six attributes that could be presented at two or four levels each. Preference estimates were estimated using a conditional logit regression model. Preference results were stratified by cancer stage.

resultsA total of 152 participants (mean age 69 years) completed the DCE in the UK, Germany, and Spain. Treatment effectiveness was the main concern for the patients (difference in preference estimates between 8 and 32 months 1.443). Participants wanted to avoid pain that was not well controlled (preference dummy coding estimate - 1.157). Participants valued a change from an oral medication to an intravenous treatment (change in preference estimate - 0.416) more negatively than a change from a 1% to a 5% risk of infection (change in preference estimate - 0.313).

conclusionsThis study shows that treatment effectiveness and pain control were the most important attributes for patients with prostate cancer. These two attributes influenced more than 50% of their decision-making in this study. The risk of fatigue and mode of administration were least prioritised by patients. This study highlights the relative importance that Spanish, German, and British patients place on various aspects of treatment options for prostate cancer. Understanding patient preference and taking them into consideration shall help physicians when developing their treatment strategies for their patients.

fundingJanssen.

Indexed as

Abiraterone AcetateAdultAgedAntineoplastic AgentsDecision MakingDocetaxelGermanyHumansMaleMiddle AgedNeoplasm StagingPatient PreferenceProstatic NeoplasmsSeverity of Illness IndexSpainSurveys and QuestionnairesAbiraterone AcetateAntineoplastic AgentsDocetaxelAbiraterone acetateDiscrete choice experimentPreferenceProstate cancer

Identifiers

PMID30617763
PMCPMC6824341
OpenAlexW2910205558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.